rec'd 1/29/04

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required	d to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449A/P	то			Complete if Known	
				Application Number	NOT YET ASSIGNED	
INFO	DRMATION	N DIS	CLOSURE	Filing Date	Concurrently	
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	Itai BAB et al.	
				Prior Group Art Unit	Not Yet Assigned	
	(use as many s	heets as	necessary)	Prior Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	31949-200571 RK	

			U.S. PATENT DOCUMEN	TS	
		U.S. Patent Document	Name of Patentee or Applicant	Date of	Pages, Columns, Lines, Where Relevan
Examiner Initials *	Cite No.1	Number Kind Code ² (if known)	of Cited Document	Publication of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
leb	AA	5,472,867	KANZ et al.	12/5/1995	
		1			

		FC	DREIGN PATENT DOCUME	NTS		
Cite No.1	Office 3	Numbo'4 Kind	Name of Patentee or Applicant of Cited	Date of Publication of Cited Document MM-DD-	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
AB AC	WO WO	94/20529 95/00166	Itai BAB et al.	9/15/1994 1/5/1995		T ₆
	No.1	Cite No.1 Office AB WO	Cite No.1 Office Number Kind (if k	Foreign Patent Document Cite No.¹ Office Number⁴ Kind Code⁵ (if known) Name of Patentee or Applicant of Cited Document AB WO 94/20529 Itai BAB et al.	Foreign Patent Document Cite No.¹ Office Number's Kind Code ⁵ (if known) Name of Patentee or Applicant of Cited Document MM-DD- YYYYY AB WO 94/20529 Itai BAB et al. Date of Publication of Cited Document MM-DD- YYYYY	Foreign Patent Document Cite No. 1 Office Number Kind Code (if known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY AB WO 94/20529 Itai BAB et al. 9/15/1994

Examiner Signature	/Lora E Barnhart/	Date Considered	10/23/2006
0.30.0.0	/LOTA E Ballillatt/	Considered	10/25/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

十 RK/trt

DC2DOCS1\518759

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box	+
ricase type a plus sign (*) maide mis dox	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/P	то			Complete if Known	
MEO	DALATION	ı Dic	CL OCUDE	Application Number	NOT YET ASSIGNED	
		_	CLOSURE	Filing Date	Concurrently	
STAT	EMENT E	BY A	PPLICANT	First Named Inventor	Itai BAB et al.	
				Group Art Unit	Not Yet Assigned	
((use as many s	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	31949-200571 RK	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2			
leb	AD CHEN, et al., "Structure-Bioactivity of C-Terminal Pentapeptide of Osteogenic Growth Peptide OGP (10-14)"; Journal of Peptide Research, Munksgaard International Publishers, Copenhagen, DK, vol. 56, no. 3, September 2000, pages 147-156					
;*						
						
·····						
			<u> </u>			

			,
Examiner Signature	/Lora E Barnhart/	Date Considered	10/23/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Comissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RK/trt

DC2DOCS1\518759

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Complete if Known

Please sign (+) inside this box Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

or form 1449A/PTO

Sheet

Application Number 10/766,527 Filing Date January 29, 2004 First Named Inventor Itai BAB Group Art Unit 1646 Examiner Name Not Assigned

(use as many sheets as necessary)

31949-200571 of 3 Attorney Docket Number

U.S. PATENT DOCUMENTS							
		U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevan		
	Cite No.1	Number Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
leb	A1	4,485,045	REGEN	11-27-1984			
i	A2	4,544,545	RYAN et al.	10-01-1985			
\sqrt{I}	A3	5,013,556	WOODLE et al.	05-07-1991			
V	A4	5,461,034	. RODAN et al.	10-24-1995			
	ΑS	3,472,867	KANZ et al.	12-05-1995	duplicate		
leb	A6	5,814,610	BAB et al.	09-29-1998			

				FOREIG	N PATENT DOCL	JMENTS				
Examiner Initials*	Cite No. ¹	Office ³	eign Patent Doo Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆		
	\ .7	WO	94/20529	A.1		09-15-1994	duplic	ate		
	A8	- WO	95/00166	Al		01-05-1995				
		ОТ	HER PRIOF	RART N	ON PATENT LITE	RATURE DOCUM	ENTS			
Examiner Initials *	Cite No.1		m (book, mag	azine, journ	al, serial, symposiur		en appropriate), title of page(s), volume-issue ned.	T²		
	100	Y.C.	CHEN et al. "St		oty of C-terminal pentage 00958947, J. Peptide Res	entide of osteogenic growth s. 2000, 56: 147-156.	pentide [OGP (10-14)]"	dur	licat	
leb	A10	S. AMSI	EL et al., "The Si	gnificance of Ir	ntramedullary Cancellous Anat. Rec.1969, 164		air of Bone Marrow Tissue",			
	All	E. ASHII	IARA et al., "FL	T-3 ligand mob	ilizes hematopoietic prin Europ. J. Haematol 199		nitor cells into blood in mice",			
	A12	I. BAB et				ed pentapeptide of osteogeni cells", J. Peptide Res. 1999,	ic growth peptide from human , 54: 408-414.			
	A13	ITAI A.	BAB, DMD, "R	egulatory Role	of Osteogenic Growth Pe Clin. Orthop. 1995,		ogenesis, and Hemopoiesis",			
	A14	GIOVA	ANNI BAROSI e			on Diagnostic Criteria for Natology 1999, 104: 730-737.			·	
	A15						of purified primitive human plantation 1999, 23: 203-209.			
	A16		WOLFRAM BRUGGER et al., "Mobilization of Peripheral Blood Progenitor Cells by Sequential Administration of Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor Following Polychemotherapy With Etoposide, Ifosfamide, and Cisplatin", Blood 1992, 79: 1193-1200.							
	A17	B. BU				colony stimulating factor (i Journal of Haematology 19				
	marrow, spleen and peripheral blood in mice", British Journal of Haematology 1990, 76: 174-179. Al8 MILOS CHVAPIL, "Pharmacology Of Fibrosis: Definitions, Limits And Perspectives" Life Sciences 1975, 16: 1345-1361.									
	A19	IANA DA	A PRATO et al., "	Differential act result	ivity of glycosaminoglyc s", Leukemia Research I	ans on colony-forming cells 999, 23: 1015-1019.	from cord blood. Preliminary			
W	A20	T.M. D	EXTER et al., "(Growth and diff	ferentiation in the hemop	oietic system", Ann. Rev. Co	ell Biol. 1987, 3: 423-441.			

leb	A21	NAGWA S. EL-BADRI et al., "Osteoblasts promote engraftment of allogeneic hematopoietic stem cells", Exp. Hematol. 1998, 26: 110-116.	
	A22	DEBORAH A. EPPSTEIN et al., "Biological activity of liposome-encapsulated murine interferon y is mediated by a cell membrane receptor", Proc. Natl. Acad. Sci. USA 1985, 82: 3688-3692.	
	A23	JOSEF FOLDES et al., "Osteogenic Response to Marrow Aspiration: Increased Serum Osteocalcin and Alkaline Phosphatase in Human Bone Marrow Donors", J. Bone Miner. Res. 1989, 4: 643-646.	
	A24	CHRISTOPHER C. FRASER et al., "Proliferation of totipotent hematopoietic stem cells in vitro with retention of long-term competitive in vivo reconstituting ability", Proc. Natl. Acad. Sci. USA 1992, 89: 1968-1972.	
	A25	NIDAL GABARIN et al., "Mitogenic G; Protein-MAP Kinase Signaling Cascade in MC3T3-E1 Osteogenic Cells: Activation by C-Terminal Pentapeptide of Osteogenic Growth Peptide [OGP (10-14)] and Attenuation of Activation by cAMP", J. Cell Bio. 2001, 81: 594-603.	
	A26	HANNA GAVISH et al., "Human α ₂ -Macroglobulin Is an Osteogenic Growth Peptide-Binding Protein", Biochemistry 1997, 36: 14883-14888.	
	A27 .	DAVID W. GOLDE, "This master cell creates the key components of the human blood cell and immune systems. Isolating and manipulating the stem cell will lead to new treatments for cancer, immune defects and other disorders", Scientific American 1991, 36-43.	
	A28	ZVI GREENBERG et al., "Mitogenic action of osteogenic growth peptide (OGP): role of amino and carboxy-terminal regions and charge", Biochim. et Biophysica Acta. 1993, 1178: 273-280.	
	A29	ZVI GREENBERG et al., "Isoloation of Osteogenic Growth Peptide From Osteoblastic MC3T3 E1 Cell Cultures and Demonstration of Osteogenic Growth Peptide Binding Proteins", J. Cellular Biochemistry 1997, 65: 359-367.	
	A30	J. GROOPMAN, "The Pathogenesis of Myelofibrosis in Myeloproliferative Disorders", Intern. Med. 1980, 92: 857-858.	
	A31	OLGA GUREVITCH et al., "Osteogenic Growth Peptide Increases Blood and Bone Marrow Cellularity and Enhances Engraftment of Bone Marrow Transplants in Mice", Blood 1996, 88: 4719-4724.	
	A32	KARL J. HWANG et al., "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study", Proc. Natl. Acad. Sci. USA 1980, 77: 4030-4034.	
	A33	ANDREW G. KING et al., "Regulation of Colony-stimulating Activity Production from Bone Marrow Stromal Cells by the Hematoregulatory Peptide, HP-5", Exp. Hematol. 1992, 20: 223-228.	
	A34	THOMAS A. LANE et al., "Harvesting and Enrichment of Hematopoietic Progenitor Cells Mobilized Into the Peripheral Blood of Normal Donors by Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) or G-CSF: Potential Role in Allogeneic Marrow Transplantation", Blood 1995, 85: 275-282.	
	A35	DONALD METCALF, "Hematopoietic Regulators: Redundancy or Subtlety", Blood 1993, 82: 3515-3523.	
	A36	MARCUS O. MUENCH et al., "Bone Marrow Transplantation With Interleukin-1 Plus kit- Ligand Ex Vivo Expanded Bone Marrow Accelerates Hematopoietic Reconstitution in Mice Without the Loss of Stem Cell Lineage and Proliferative Potential", Blood 1993, 81: 3463-3473.	
	A37	G. MOLINEUX et al., "The Effects on Hematopoiesis of Recombinant Stem Cell Factor (Ligand for c-kit) Administered In Vivo to Mice Either Alone or in Combination With Granulocyte Colony-Stimulating Factor", Blood 1991, 78: 961-966.	
	A38	SEAN J. MORRISON et al., "The purification and characterization of fetal liver hematopoietic stem cells", Proc. Natl. Acad. Sci. USA 1995 92: 10302-19306.	
	A39	CHRISTA E. MÜLLER-SIEBURG et al., "The Stromal Cells' Guide to the Stem Cell Universe", Stem Cells 1995, 13: 477-486.	
	A40	HARVEY M. PATT et al., "Bone Marrow Regeneration after Local Injury", Exp. Hemat. 1975, 3: 135-148.	
	A41	LOUIS M. PELUS et al., "In vivo modulation of hematopoiesis by a novel hematoregulatory peptide", Exp. Hemat. 1994, 22: 239-247.	
	A42	SHAHIN RAFII et al., "Human Bone Marrow Microvascular Endothelial Cells Support Long-Term Proliferation and Differentiation of Myeloid and Megakaryocytic Progenitors", Blood 1995, 86: 3353-3363.	
	A43	VIVIENNE I. REBEL et al., "Amplification of Sca-1* Lin "WGA* Cells in Serum-Free Cultures Containing Steel Factor, Interleukin-6, and Erythropoietin With Maintenance of Cells With Long-Term In Vivo Reconstituting Potential", Blood 1994, 83: 128-136.	
	A44	D. ROBINSON et al., "Osteogenic Growth Peptide Regulates Proliferation and Osteogenic Maturation of Human and Rabbit Bone Marrow Stromal Cells", J. Bone and Min. Res. 1995, 10: 690-696.	
	A45	RUSSELL S. TAICHMAN et al., "Human Osteoblasts Support Human Hematopoietic Progenitor Cells in In Vitro Bone Marrow Cultures", Blood 1996, 87: 518-524.	
	A46	NICOLA VOLPI et al., "Effects of Glycosaminoglycans on U-937 Leukemia Cell Proliferation and Differentiation: Structure-Function Relationship, Exp. Cell Res. 1994, 215: 119-130.	
V	A47	JAMES D. WATSON et al., "Novel Factors From Stromal Cells: Bone Marrow and Thymus Microenvironments", Int. J. Cell Cloning 1992, 10: 144-152.	

leb	A48	DAVID A. WILLIAMS, "Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells Robbing Peter to Pay Paul?", Blood 1993, 81: 3169-3172.	
leb	A49	JOHN P. WINEMAN et al., "Maintenance of High Levels of Pluripotent Hematopoietic Stem Cells In Vitro: Effect of Stromal Cells and c-kit", Blood 1993, 81: 365-372.	

Examiner Signature	/Lora E Barnhart/	Date Considered	10/23/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450..





¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (07-05)

Under the Paperwork Reduce of Act of 1995, no persons are	U.S. Patent e required to respond to a collection	and Trademark Office; U.S. DEPARTMENT OF COMMERCE of Information unless it contains a valid OMB control number. Complete if Known
Substitute for forms BRA	Application Number	10/766,527
INFORMATION DISCLOSURE	Filing Date	01/29/2004
STATEMENT BY APPLICANT	First Named Inventor	BAB, Itai
(Use as many sheets as necessary)	Art Unit	1646
(use as many sneets as necessary)	Examiner Name	
Sheet 1 of 1	Attorney Docket Number	31949-200571 RK

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
leb		Bab, I., et al., Endocrinology, 123(1);345-352 (1988)	
		Erratum which refers to: Bab, I., et al., Endocrinology, 128(5) 2638 (1991)	
		Kharchenko et al., Vepr. Med. Khim., 35(2) 106-109, (1989) (abstract)	
V		Taichman, R.S., et al., Hematol. 4:421-426 (2000)	

Examiner	/Lora E Barnhart/	Date	10/23/2006
Signature	• • • • • • • • • • • • • • • • • • • •	Considered	• •

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.